Department of Biochemistry and Molecular Pharmacology
Cancer Biology | Neoplasms | Therapeutics
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
angiogenesis, autophagy, imidazotetrazine, MGMT, DNA repair, temozolomide, cancer stem cells, UMCCTS funding
DOI of Published Version
Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475. Link to article on publisher's website
Ramirez Y, Weatherbee JL, Wheelhouse RT, Ross AH. (2013). Glioblastoma multiforme therapy and mechanisms of resistance. GSBS Student Publications. https://doi.org/10.3390/ph6121475. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/1869